- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
HIFU Proves Noninferior to Radical Prostatectomy in Localized Prostate Cancer
May 3rd 2024, 8:39pm
American Urological Association Annual Meeting
High-intensity focused ultrasound produced noninferior salvage treatment-free survival vs radical prostatectomy in localized prostate cancer.
Dr Tyson on the Phase 3 BOND-003 Trial in BCG-Unresponsive NMIBC With CIS
May 3rd 2024, 7:46pm
American Urological Association Annual Meeting
Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
April 20th 2024, 10:00am
Idalid Franco, MD, MPH, discusses the integration of immunotherapy, molecular biomarkers, and risk factors for recurrence into the endometrial cancer paradigm.
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
April 17th 2024, 6:35pm
Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
April 16th 2024, 8:20pm
Itacitinib prophylaxis showed signals for reducing CRS and ICANS following treatment with axicabtagene ciloleucel in patients with B-cell lymphoma.
Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC
April 16th 2024, 7:02pm
European Association of Urology Congress
Serial testing of ctDNA could improve risk stratification for determining adjuvant treatment in patients with high-risk muscle-invasive bladder cancer.
Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer
April 16th 2024, 6:00pm
European Association of Urology Congress
Adjuvant nivolumab extended DFS, NUTRFS, and DMFS vs placebo and showed for the first time an improvement in OS in patients with high-risk muscle-invasive urothelial cancer.
Simulations Improve CAR T-Cell Therapy Understanding and Administration Confidence
April 15th 2024, 7:55pm
Simulation-based education can improve health care professionals’ understanding and confidence regarding the treatment of patients with CAR T-cell therapy.
Orca-T May Be a Suitable Option Over PTCy-Based HSCT in Acute Leukemia and MDS
April 15th 2024, 7:39pm
Orca-T demonstrated positive impacts on relapse-free survival and overall survival vs PTCy-based HSCT in acute leukemias and myelodysplastic syndrome.
Orca-T Proves Safe and Effective in Advanced Hematologic Malignancies
April 15th 2024, 7:00pm
The regulatory T cell enriched donor cell agent Orca-T was safe and displayed activity in the reduced intensity conditioning setting for patients with advanced hematologic malignancies.
Nadofaragene Firadenovec Showcases Sustained Responses in BCG-Unresponsive NMIBC
April 12th 2024, 1:47pm
The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.
Insider Insights: Unveiling Takeaways from AACR 2024
April 11th 2024, 6:54pm
Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
April 10th 2024, 11:53pm
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Savolitinib/Osimertinib Yields Responses in EGFR-Mutant, MET-Amplified, Osimertinib-Resistant NSCLC
April 10th 2024, 7:45pm
Responses with savolitinib plus osimertinib were higher in patients with NSCLC who had higher MET amplification cutoffs vs the overall population.
Novel CAR T-Cell Therapy HR001 Demonstrates Efficacy in R/R Non-Hodgkin Lymphoma
April 10th 2024, 4:42pm
The novel CAR T-cell agent HR001 was effective, with durable responses and a favorable safety profile observed, in relapsed/refractory non-Hodgkin lymphoma.
RGI-2001 Plus Tacrolimus/Methotrexate Demonstrates Protective Effect From Acute GVHD Post Allo-HSCT
April 10th 2024, 4:33pm
Prophylactic treatment with RGI-2001 plus tacrolimus and methotrexate led to a lower incidence of acute GVHD vs CIBMTR control following allo-HSCT.
PSMA-Directed Targeted Alpha Therapy Shows Activity in Heavily Pretreated Metastatic CRPC
April 10th 2024, 3:01pm
FPI-2265 showed promising activity in patients with metastatic castration-resistant prostate cancer which was similar to prior safety and efficacy data reported.
Proteogenomic Signatures Shed Light on Prostate Cancer Recurrence Risk in Select Ancestries
April 10th 2024, 1:25am
A proteomics analysis revealed significant variations in protein expression and informative markers between African vs European prostate tumors.
Dr Christenson on Copanlisib Plus Nivolumab in Pretreated PIK3Ca+ MSS mCRC
April 9th 2024, 10:57pm
Eric S. Christenson, MD, discusses efficacy data for copanlisib plus nivolumab in patients with pretreated, MSS metastatic colorectal cancer.